Significant bone density increases observed with romosozumab after a year of treatment

Romosozumab is an effective treatment for osteoporosis, demonstrating significant improvements in bone mineral density and a reduced risk of vertebral fractures, according to a study.

The study analyzed data from 20 trials involving 13,507 participants (637 men and 12,870 women). After 12 months of romosozumab treatment, significant improvements in bone mineral density were observed, with mean differences of 10.04 at the lumbar spine, 4.04 at the total hip, and 3.77 at the femoral neck (P < 0.00001).

Romosozumab showed a reduced likelihood of new vertebral fractures compared to control groups, with odds ratios of 0.42 at 12 months and 0.36 when followed by anti-resorptive therapy for 24 months. The safety profile of romosozumab was comparable to control treatments, with no significant differences in serious or fatal adverse events, including cardiovascular events.

Reference
Wong RMY, Wong PY, Liu C, et al. Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis. J Orthop Translat. 2024;48:107-122. doi: 10.1016/j.jot.2024.07.011. PMID: 39189010; PMCID: PMC11345130.